Technetium-99m-sestamibi uptake by recurrent Hurthle cell carcinoma of the thyroid.
Technetium-99m-sestamibi has been reported to localize in various tumors. Scintigraphic results for a patient with recurrent Hurthle cell carcinoma of the thyroid whose tumor was imaged with both 99mTc-sestamibi and 201TI, but not with 131I, are presented.
Balon
H R
HR
Nuclear Medicine Department, William Beaumont Hospital, Royal Oak, Michigan 48073-6769.
Fink-BennetT
D
D
Stoffer
S S
SS
D000368:Aged; D002277:Carcinoma / Q000000981:diagnostic imaging* / Q000378:metabolism; D006801:Humans; D007457:Iodine Radioisotopes; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000000981:diagnostic imaging* / Q000378:metabolism; D015609:Organotechnetium Compounds / Q000493:pharmacokinetics*; D011877:Radionuclide Imaging; D017256:Technetium Tc 99m Sestamibi; D013794:Thallium Radioisotopes; D013964:Thyroid Neoplasms / Q000000981:diagnostic imaging* / Q000378:metabolism
D007457:Iodine Radioisotopes; D015609:Organotechnetium Compounds; D013794:Thallium Radioisotopes; D017256:Technetium Tc 99m Sestamibi